Literature DB >> 8883427

Angiogenesis: a critical process in the pathogenesis of RA--a role for VEGF?

E M Paleolog.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8883427     DOI： 10.1093/rheumatology/35.10.917

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN： 0263-7103


× No keyword cloud information.
  29 in total

Review 1.  Future prospects for anti-cytokine treatment.

Authors:  M Feldmann; J Miotla; E Paleolog; R Williams; A M Malfait; P Taylor; F M Brennan; R N Maini
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 2.  Angiogenesis as a target in rheumatoid arthritis.

Authors:  A E Koch
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  Angiogenic growth factors in rheumatoid arthritis.

Authors:  Malte Schroeder; Lennart Viezens; Ina Fuhrhop; Wolfgang Rüther; Christian Schaefer; Britta Schwarzloh; Petra Algenstaedt; Bernd Fink; Nils Hansen-Algenstaedt
Journal:  Rheumatol Int       Date:  2011-11-09       Impact factor: 2.631

4.  Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies.

Authors:  E M Paleolog; R A Fava
Journal:  Springer Semin Immunopathol       Date:  1998

5.  The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes.

Authors:  Takuma Kusabe; Yuko Waguri-Nagaya; Tomohiro Tanikawa; Mineyoshi Aoyama; Muneyoshi Fukuoka; Masaaki Kobayashi; Takanobu Otsuka; Kiyofumi Asai
Journal:  Rheumatol Int       Date:  2005-07-01       Impact factor: 2.631

6.  Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study.

Authors:  Johannes Strunk; Elisabeth Bundke; Uwe Lange
Journal:  Rheumatol Int       Date:  2005-07-06       Impact factor: 2.631

7.  Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.

Authors:  P A Klimiuk; S Sierakowski; R Latosiewicz; J P Cylwik; B Cylwik; J Skowronski; J Chwiecko
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

8.  Fine-mapping resolves Eae23 into two QTLs and implicates ZEB1 as a candidate gene regulating experimental neuroinflammation in rat.

Authors:  Pernilla Stridh; Melanie Thessen Hedreul; Amennai Daniel Beyeen; Milena Z Adzemovic; Hannes Laaksonen; Alan Gillett; Johan Ockinger; Monica Marta; Hans Lassmann; Kristina Becanovic; Maja Jagodic; Tomas Olsson
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

9.  Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.

Authors:  Norihiro Nishimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Mod Rheumatol       Date:  2008-11-01       Impact factor: 3.023

10.  Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis.

Authors:  Stacy M Plum; Eun J Park; Steve J Strawn; Elizabeth G Moore; Carolyn F Sidor; William E Fogler
Journal:  BMC Musculoskelet Disord       Date:  2009-05-01       Impact factor: 2.362
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.